

May 11, 2017
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Notice Concerning Non-operating Expenses

SymBio Pharmaceuticals Limited (“the Company”) announces accrued non-operating expenses for the first quarter of the fiscal year ended December 31, 2017 (from January 1, 2017 to March 31, 2017).

1. Details of Non-operating Expenses

The Company recorded a foreign exchange loss of 55,197 thousand yen under non-operating expenses for the first quarter of the fiscal year ended December 31, 2017 (from January 1, 2017 to March 31, 2017) due to recent fluctuations in foreign exchange rates.

2. Future Outlook

Based on its assumption concerning operational trends for this fiscal year, the Company determined that these non-operating expenses would have no significant impact on the results of operations for the year with no modification to the financial forecast required. The Company will make a prompt announcement should any modification to the financial forecast be necessary.

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125